Friday, July 17, 2026

pharma · Diabetes Mellitus · Hemophilia A

Takeda

Takeda is a pharma organization headquartered in Cambridge, USA. Primary therapeutic focus areas include Diabetes Mellitus, Hemophilia A, Crohn's Disease, Hypertension, Type 2 Diabetes Mellitus. NovaPharmaNews links 1179

Cambridge, USA HQ
1993 Founded
1,617 Employees
NMPA registrant Type
Company details
Status
Public
HQ
Cambridge, USA
Founded
1993
Employees
1,617
Programs
1179
Drugs
283
Patents
1436
Clinical program

Pantoprazole

Phase 3 · small molecule · Gastroesophageal Reflux Disease (GERD)

Pantoprazole for Gastroesophageal Reflux Disease (GERD) is a Phase 3 program (small_molecule) at Takeda with 2 ClinicalTrials.gov record(s).

← All Takeda projects Phase 3 small molecule completed

Internal code BY1023/M3-341

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Takeda
Phase
Phase 3
Modality
small_molecule
Indication
Gastroesophageal Reflux Disease (GERD)
Status
completed
Trials
2